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In 1996, the results were published of a randomized, controlled
trial evaluating 'high-dose' interferon alpha 2b (IFN-a) in patients
at high risk of recurrence after surgery for thick primary or
regional lymph node-positive malignant melanoma (Kirkwood et
al, 1996). In this study conducted by the Eastern Cooperative
Oncology Group (study E1684), 287 patients were randomized
after primary resection to observation alone or to receive IFN-a,
20 MU m-2 by 1-h intravenous infusion, days 1-5 for 4 weeks
(induction), followed by 10 MU m-2 subcutaneously, three times a
week for 48 weeks (maintenance).
Analysis of the data at median follow-up of 6.9 years showed a
significant prolongation ofrelapse-free (P = 0.0023, one-tailed test)
and overall survival (P = 0.0237, one-tailed test) in favour of WN-a
therapy. This study is the first and only randomized, prospective
trial to date that has shown durable statistically significant survival
benefit from any medical therapy after surgery forlocally advanced
melanoma. In response, the United States Food and Drug
Administration granted a licence for adjuvant IFN-ax and, since
then, the E1684 high-dose IFN-a regimen (alternatively known as
the Kirkwood regimen) has become the standard arm in any newly
established randomized trial of adjuvant therapy undertaken in the
USA in patients with stage IIB and III (American Joint Committee
on Cancer staging system, AJCC) malignant melanoma.
IFN-ax was licensed for adjuvant use in melanoma in the UK in
July 1997. However, significant controversy surrounds the
rationale for using this expensive, potentially toxic therapeutic
modality. Uncertainty hinges on the requirement for an adequate
evidence basejustifying treatment. Current clinical status of adju-
vant IFN-a - arguments both for and against its use - are outlined
here, with the intention offacilitating a move towards a consensus
among those involved in melanoma patient care.
THE PATIENT POPULATION JUSTIFIES
INVESTMENT OF RESOURCES
Malignant melanoma currently represents around 1% of all new
cancer cases in the UK. Unlike the more common solid tumours, it
is a disease often affecting young adults: median age at presenta-
tion is below 50 years (OPCS, 1994). Furthermore, the incidence
of melanoma is increasing at a rate faster than for any other
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tumour, currently doubling every 6-10 years. Despite evidence
that more individuals are presenting with localized, resectable
disease, the death rate is increasing by around 5% per year.
Malignant melanoma can behave unpredictably, but studies have
shown that, for patients with thick primary tumours (> 4mm
Breslow depth, T4, AJCC stage IIB tumours) and/or regional
lymph node involvement (AJCC stage III tumours), over 50% of
patients will relapse or die of recurrent disease within 2 years of
surgery. When recurrent disease is not amenable to surgery, no
medical therapy has yet been shown to impact on survival. Thus,
while patients with disseminated disease are considered candidates
for phase I trials of novel anti-cancer modalities, there is a clear
imperative to define an effective adjuvant therapy that will reduce
the risk ofdisease recurrence after primary melanoma surgery.
BIOLOGICAL AGENTS HOLD THE GREATEST
PROMISE AS SYSTEMIC THERAPY
Conventional cytotoxics tested in patients with advanced disease
have been shown to achieve response rates of, at best, 20-25% as
single agents and 50-60% in dose-intensive combination regimens
(reviewed in McClay and McClay, 1996). However, no
chemotherapy regimen to date has been shown to prolong patient
survival significantly. Thus, single-agent dacarbazine (response
rate around 20%) remains the mainstay ofstandard therapy outside
clinical trials. Early randomized trials of adjuvant therapy in
melanoma using dacarbazine (e.g. Kerin et al, 1995), combination
chemotherapy (e.g. Meisenberg et al, 1993), bacille Calmette-
Guerin (BCG; Tan and Ho, 1993) and other modalities, including
levamisole (e.g. Parkinson, 1991; Spitler, 1991) and vitamin A
(Meyskens et al, 1994) have not demonstrated any survival
advantage with treatment compared with surgery alone.
There is now a wealth of evidence that the immune system can
influence the natural history ofmelanoma, and a variety ofbiolog-
ical agents has been shown to possess antitumour activity both in
vitro and in vivo. Monoclonal antibodies raised against tumour-
specific antigens (e.g. antigens encoded by the MAGE gene
family, tyrosinase, Melan-A/MART), active immunotherapy by
vaccination with, in particular, melanoma-specific gangliosides,
and intensive biochemotherapy regimens are currently being
explored in early clinical trials (Balch et al, 1997). Considerable
trial experience has already been gained with the type I (IFN-a
and -, subtypes) and type II (IFN-y) interferons as well as inter-
leukin 2 (IL-2), as single agents and in combination regimens, in
both the advanced and the adjuvant setting.
12871288 PG de Takats etal
Table 1 Objective response rates observed with interferon alpha in published trials, compared with the most active single-agent chemotherapy drugs
Agent Schedule Evaluable Response Reference(s)
patients (PR + CR)
n(%)
Dacarbazine 1936 382 (20) Balch et al (1993)
Fotemustine 226 56 (25) McClay and McClay (1996)
Cisplatin 188 43(23) Balch et al (1993)
Temozolamide 56 12 (21) Bleehan et al (1995)
IFN-a-2a 12-50 MU m-2 i.m. t.i.w. 79 15 (19) Creagen et al (1984) Hersey et al (1985)
IFN-a-2a 9-36 MU i.m. Daily 64 4 (11) Legha et al (1987), Steiner et al (1987), Elsasser-Beile et al (1987)
IFN-a-2a 20 MU m-2 i.v. Daily for 5 of 14 days 15 0 (0) Coates et al (1986)
IFN-a-2b 10 MU s.c. t.i.w. 22 6 (27) Dorval et al (1986)
IFN-a-2b 10 MU m-2 i.m. t.i.w. 21 3 (14) Sertoli et al (1989)
IFN-a-2b 10 MU m-2 s.c. t.i.w. for 12 weeks 40 10 (25) Robinson et al (1986)
IFN-a-2b 10-100 MU i.m. or i.v. Daily for 28 days 23 5 (22) Kirkwood et al (1985)
Recombinant IFN-a has shown broad-spectrum immunomodu-
latory and antiproliferative activity in a variety of human malig-
nancies, including melanoma. Disappointingly, IFN-a appears to
achieve overall response rates no better than the most active
single-agent chemotherapy drugs (Tables 1 and 2). However, some
5% of patients consistently achieve complete responses, which
appear to be durable, associated with long-term survival (Creagan
et al, 1988; Legha, 1997). Despite more than a decade of trial
work, the optimal dose and scheduling of IFN-a has not been
established. Efficacy and toxicity appear to be both dose and time
dependent: higher doses induce more complete responses of
longer duration while being more toxic; delayed responses are
documented after several months of treatment; a wide variety of
recognized IFN-a-related side-effects limit tolerance of treatment
(Table 3).
DOES ADJUVANT INTERFERON OFFER
SURVIVAL BENEFIT?
The early trials of adjuvant melanoma immunotherapy failed to
show prolongation ofpatient survival (Fisher et al, 1981; Kaiser et
al, 1981; Veronesi et al, 1982), but the role of the recombinant
IFNs had yet to be tested. All subtypes of IFN have now been
explored to prevent melanoma recurrence after disease resection.
IFN-yhas shown minimal anti-tumour activity against melanoma,
and the negative randomized trial ofadjuvant IFN-yundertaken by
the South West Oncology Group suggested possible adverse
effects in the treatment arm (Meyskens et al, 1990, 1995). Several
trials of adjuvant IFN-a have been undertaken globally, and
Table 4 summarizes completed and ongoing phase III IFN-a
studies in high-risk patients. Until now, all such studies have
randomized against an observation-only arm.
From currentdata available from these studies, the value ofadju-
vant IFN-a remains uncertain. The completed studies of low-dose
therapy are not yet mature. However, two such studies have
suggested possible patient benefit. The WHO melanoma Program
Trial 16 study randomized 444 patients with histologically proven
lymph node-positive disease between June 1990 and January 1994
to receive either IFN-a-2a 3 MU flat dose administered subcuta-
neously (s.c.) three times a week for 3 years, or no treatment after
surgery. An early interim analysis indicated highly significant
prolongation ofdisease-free survival for all treated patients and an
overall survival benefit forsome subgroups (Cascinelli etal, 1994).
However, 1 year later, the survival curves converged and the study
has not shown durable survival benefit (Cascinelli, 1995). The
French Cooperative Group on Melanoma have evaluated the same
drug and dose (but treatment period 18 months) in 499 patients
with > 1.5-mm-thick primary lesions without clinically detectable
lymph node involvement. The first published results, at median
follow-up of 2.3 years, indicated no overall survival difference
between treated anduntreatedpatients (Grob etal, 1996). However,
by June 1995, at median follow-up of 3 years, a statistical prolon-
gation of both relapse-free (P= 0.029, two-sided) and overall
survival (P= 0.011, two-sided) was evident in favour of IFN-a
therapy. The results ofa 1997 reanalysis are awaited with interest.
The only conventional phase I pharmacokinetic dose-escalation
studies with IFN-a were undertaken by ECOG in the early 1980s.
Assessing drug administered by eitherthe intravenous (i.v.) orintra-
muscular (i.m.) route, they determined that 20 MU m-2 could be
safely given to patients on a daily basis with manageable side-
effects (Kirkwoodetal, 1985). Thus, trials wereundertaken todeter-
mine theroleofmuchhigherdoses ofIFN-ain the adjuvantsetting.
The results of two high-dose studies have been published to
date. E1684 has shown both statistically significant prolongation
in disease-free and overall survival with adjuvant IFN-a-2b by
9 months and 12 months respectively (Kirkwood et al, 1996).
However, a study by the North Central Cancer Trials Group
(NCCTG) randomized 262 patients with primary tumours
> 1.69 mm thick or nodal involvement to receive IFN-a-2a
20 MU m-2 i.m. three times a week for 12 weeks. At median
follow-up of 6.1 years, neither disease-free nor overall survival
were significantly greater with treatment (Creagan et al, 1995).
In the UK, currently, standard therapy for stage I-ITT melanoma
remains surgical excision oftumour. Interested, motivated oncolo-
gists are likely to be offering high-risk patients entry to one oftwo
ongoing phase III adjuvant IFN-a studies: the UKCCCR-
sponsored Aim High study randomizes patients on a 1:1 basis to
receive either 'low-dose' IFN-a-2a (3 MU s.c. three times per
week for 2 years) or to observation only; the EORTC 18952 study
randomizes patients to receive either 'internediate-dose' IFN-a-2b
(10 MU s.c. daily x5 for 4 weeks, followed by maintenance
therapy with either 10 MU s.c. three times per week for 1 year or
5 MU s.c. three times per week for 2 years) vs observation. The
EORTC study is skewed such that four in every five patients will
receive IFN-a.
Both European studies were initiated at a time when the prelim-
inary results ofE1684 were known. At that time, a healthy scepti-
cism among UK oncologists prevailed (Williams et al, 1997); the
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Table 2 Randomized trials comparng interferon alpha plus dacarbazine with dacarbazine in patients with metastatic cutaneous melanoma
Study Regimen No. of Response Median overall
patients rate(%) survival (months)
Falkson et al (1991) DTIC 200 mg m-2 dl-5 vs 31 20 9.6
DTIC 200 mg m-2 dl-5 +
IFN-a-2b 15 MU m-2 i.v. daily x 3/52, 30 53 17.6 P= 0.01
then 10 MU m-2 s.c. t.i.w.
Thomson et al (1993) DTIC 800 mg m-2 dl vs 83 17 7.5
DTIC 200-800 mg m-2 dl +
IFN-a-2a 3-9 MU m-2 s.c. t.i.w. 87 21 8.8 NS
Bajetta et al (1994) DTIC 800 mg m-2 dl q3/52 vs 82 20 11
DTIC 800 mg m-2 dl q3/52 +
IFN-a-2a 3 MU i.m. t.i.w. vs 84 23 11
DTIC 800 mg m-2 dl q3/52 +
IFN-a-2a 9 MU i.m. daily 76 28 13 NS
Falkson et al (1996) DTIC 200 mg m-2 dl-5 vs 67 12
DTIC 200 mg m-2 dl-5 +
IFN-a-2b 15 MU m-2 i.v. daily for 3/52, 65 21 - NS
then 10 MU m-2 s.c. t.i.w.
DTIC, dacarbazine; t.i.w., three times a week; NS, no statistically significant difference.
Table 3 Recognized side-effects associated with interferon alpha therapy, in
order offrequency
Flu-like symptoms
Fatigue/lethargy
Neutropenia
Lymphopenia
Fever
Myalgia
Anorexia
Nausea/vomiting
Elevated liver transaminases
Headache
Chills/rigors
Depression
Altered mood
Loss of concentration
Diarrhoea
Abdominal pain
Alopecia
Altered taste sensation
Dizziness/vertigo
Anaemia
Rarely
Jaundice
Liver failure
Severe psychological disturbance (suicidal depression)
Behavioural changes
Confusion
Cortical blindness
Retinopathy
Leukoencephalopathy
ECOG study randomized a small number ofpatients (n = 287) and
analysed the data using a one-tailed Student's t-test, so presup-
posing that treatment would be superior to no treatment. The toxi-
city associated with IFN-a doses used by ECOG was excessive by
European standards: more than two out of three patients overall
required dose reduction or delay and two patients died 1 and 3
months into treatment from liver failure. Notably, when the orig-
inal study data were reanalysed taking into account toxicity,
overall quality of life adjusted survival was no longer statistically
significantusing a two-tailed test (Cole et al, 1996).
Recruitment to theseEuropean studies has beendisappointingly
poor. By October 1997, 2 years after its launch, 212 patients had
been entered from 23 UK centres in to Aim High: a study that
requires 1000 patients to define a 10% difference in recurrence-
free and overall survival (90% power). Recruitment to the EORTC
study is more promising, averaging 40-50patients permonth, and
is predicted to achieve the recruitment target of 1000 patients by
the year 1999. However, few centres from the UK are actively
contributing to this study. So what is happening to eligible
patients? It appears that the Kirkwood regimen is being increas-
inglyprescribed outside ofany clinical trial, both as aconsequence
of pressure from well-informed patients surfing the internet, but
also because oncologists have been convinced by the results of a
single randomized trial.
IS ONE STUDY ENOUGH?
Any new treatment should be established by comparison against
current standard therapy in a randomized prospective controlled
trial. However, as indicated by E1684, the design ofany one study
may itself be considered to be flawed and, therefore, convention
requires that twoindependent studies arerequired tojustifychange
ofpractice. Even then, a statistical P-value cannot in itself define
the new standard - for example, exactly how much longer do
patients live with treatment? What are the costs topatients in terms
ofquality oflife (Cole etal, 1996)? What are the resourceimplica-
tions of introducing the new therapy (Hillner et al, 1997)? - we
must account for cost ofdrug, plus drug-induced toxicity that may
includeprophylactic medication, hospital admissions and days lost
from work. And to what extent must we consider the opportunity
cost for other patients in a resource-limited health system?
Appropriately, after closing the first study, ECOG undertook a
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Table 4 Completed and current randomized trials of adjuvant interferon alpha in patients with resected malignant melanoma at high risk of recurrence
Trial Eligible Interferon schedule Planned Total no. Comments
patientsa total dose of patients
IFN-a-2b induction: 20 MU m-2
daily i.v. x 4 weeks
then maintenance: 10 MU m-2
t.i.w. s.c. x 48 weeks
IFN-a-2b induction: 20 MU m-2
daily i.v. x 4 weeks,
then maintenance: 10 MU m-2
t.i.w. s.c. x 48 weeks
vs 3 MU t.i.w. s.c. x 2 years
T3-4, Ni IFN-a-2b 20 MU m-2
daily i.m. x 3 months
T4, Ni IFN-a-2b induction:
10 MU daily s.c. x 4 weeks
then maintenance:
10 MU t.i.w. s.c. x 1 year or
5 MU t.i.w. s.c. x 2 years
T4, N1-2 IFN-a-2a 3 MU t.i.w. s.c. x 3 years
T4, N1-2 IFN-a-2a 3 MU t.i.w. s.c. x 2 years
3500 MU 287 Significant difference in DFS:
1.72 vs 0.9 years (P= 0.004)
Significant difference in OS:
3.82 vs 2.78 years (P= 0.046)
3500 MU 642 Study closed - results awaited May 1998
1400 MU
2210 MU 262 No significant difference in DFS:
2.7 vs 2 years (P= 0.19)
or OS: 6.6 vs 5 years (P= 0.40)
1760 MU 1000C Continues to recruit in Europe
1400 MU 444 At median follow-up 3.25 years
no significant difference in DFS orOS
936 MU 1000C Continues to recruit in UK
French Consortium
Austrian Melanoma Cooperative
Scottish Melanoma Group
T3-4
T3-4
T3-4
IFN-a-2a 3 MU t.i.w. s.c. x 18 months
IFN-a-2a induction:
3 MU daily s.c. x 3 weeks
then maintenance:
3 MU t.i.w. s.c. x 1 year
IFN-a-2a 3 MU t.i.w. s.c. x 6 months
702 MU
513 MU
234 MU
499 At median follow-up 3 years, significant
difference in DFS (P= 0.029) and
OS (P= 0.011)
No interim analysis yet
92 No survival difference to date
T3-4, N1-2 IFN-a-2b 1 MU alt days s.c. x 1 year
vs IFN-yx 1 year
182 MU 830 Closed April 1996: no survival
difference so far
aAmerican JointCommittee on Cancer staging system (1992): T3 is stage IIA, T4 is stage IIB, N1,2 is stage Ill. blntergroup study: ECOG
E1690/SWOG9111/CALGB9190. N.B. this study differs from El684 in that lymphadenectomy was required for patients with T4 primary melanomas in E1684, but
not required in the latertrial. cPlanned total recruitment number. References for published studies: Kirkwood et al (1996) (ECOG 1684); Creagen et al (1995)
(NCCTG 83-7052); Cascinelli (1995) (WHO 16).
second adjuvant melanoma trial as part of an Intergroup trial
(E1690/SWOG9111/CALGB9190), which randomized 642
patients after melanoma resection to receive either the Kirkwood
regimen, low-dose IFN-a as per the Aim High study or to obser-
vation. The results of this pivotal study will become known later
this year and, clearly, will determine whether high-dose IFN-a is
the treatment ofchoice for these patients.
DETERMINING STANDARD ADJUVANT
THERAPY
While awaiting the results of E1690, given the time and effort
required to organize a multicentre trial, it is necessary to plan well
in advance. We can do this by considering our response to the
possible outcomes ofthis study. Let us suppose that E1690 shows
no statistical survival benefit of high-dose IFN-a over either low-
dose IFN-a or observation. Both purchasers and providers could
be forgiven for breathing a heavy sigh of relief - doctors and their
patients will be disappointed.
Is there achance that the low-dose IFN-a arm could show benefit
over observation? Given the current analysis of the French
Consortium study, this possibility should not be ruled out. It is prob-
ably reasonable to assume that, as long as the high-dose IFN-a arm
ofE1690 does not show statistical survival benefit over either other
arm, UK oncologists would be justified in continuing to support
both Aim High and EORTC 18952, in which both studies address
other key end points, such as quality of life, health economics and
molecular prognostic indicators in addition to patient survival. Our
ability to contribute to such important clinical trials, however, could
potentially be seriously impeded as aconsequence ofpremature drug
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licensing. Cancer centres will find it difficult to absorb the cost of
IFN-a, estimated to be approximately £10 000 and £5500 per
treated patient within the EORTC 18952 and Aim High studies
respectively. The predicament of resourcing clinical research
involving expensive drugs must be raised both with the public and
the politicians as a matter of urgency if we are to fulfil our ethical
and medical obligations topatients.
Now let us suppose that E1690 clearly shows survival benefit
withhigh-dose IFN-a over low-dose therapy and observation. The
criteria for defining a new standard therapy will be met and oncol-
ogists will be duty-bound to address key issues: is it unethical not
to offer some form of IFN-a to patients at high risk and, by the
same argument, therefore to continue to recruit to the European
adjuvant studies? If ethically duty-bound to treat, do we realisti-
cally have access to the necessary resources - finances, specialist
staff, in-patient and out-patient facilities? a pharmacoeconomic
analysis undertaken on the basis ofE1684 (Hillner et al, 1997) has
calculated the cost of high-dose IFN-a per life year gained to be
around $13 700 after 35 years. This figure equates with the cost-
effectiveness of adjuvant chemotherapy for node-negative breast
cancer, while being 30-50% cheaper than taxol used as first-line
therapy in ovarian cancer. However, the absolute drug cost of
around £20 000 per treated patient will not be easily forthcoming
from purchasers within the UK.
THE WAY FORWARD
With the knowledge available to us, one could apply forethought
and consider future initiatives in management of high-risk
melanoma patients. Are we yet ready to design the next adjuvant
study should E1690 confirm survival benefit with high-dose
IFN-a? Alternatively, has the patient population who may benefit
from adjuvant therapy been adequately defined?
One obvious key question relates to the scientific rationale for
high-dose IFN-a as defined by the Kirkood regimen. The mecha-
nism by which high-dose therapy actually works is unknown. To
our knowledge, no true dose-response relationship has been
demonstrated for IFN-a in terms of immune modulation. It has
been argued that the route ofadministration ofthe induction phase
in the Kirkwood regimen - i.v. rather than s.c. - is the key to effi-
cacy. The original pharmacokinetic study (Kirkwood et al, 1985)
showed that, while IFN-a was detectable in serum after 24 h only
after i.m. administration, significantly higherpeak plasma concen-
trations were achieved with i.v. drug administration. As the
survival curves separated early in E1684, the high peak plasma
levels achieved by i.v. drug administration in the first month may
confer the pharmacological advantage in eradicating micro-
metastatic disease. This theory has, however, yet to be adequately
substantiated. Furthermore, although the randomized NCCTG trial
of short-term, high-dose i.m. IFN-a (Creagan et al, 1995) is
usually regarded as showing no benefit over surgery alone, the
difference in median disease-free survival for node-positive
patients (17 vs 10.8 months) was significant when adjusted for
other parameters in a Cox model (P = 0.04). Taken together, there
appears goodjustification forevaluating the benefits ofshort-term,
high-dose IFN-a regimens compared with the 1-year Kirkwood
regimen. Ifequivalence could be proven, then savings in terms of
drug costs, hospital resources, patient toxicity and quality of life
are likely to be substantial. Such a result might be pertinent to the
management of other tumour types, such as lymphomas and renal
cell carcinomas, in which IFN-a plays a role.
It might be possible to build into such an equivalence study an
assessment of survival benefit by incorporating other strategies of
immune modulation. For example, serology studies have shown
that patients who develop antibodies against melanoma-specific
cell-surface glycolipids, known as gangliosides, have a favourable
prognosis. The purified ganglioside GM2 has been administered to
patients with an immune adjuvant (BCG) to augment the antibody
response elicited by GM2 antigen. In a randomized trial conducted
in 122 stage III melanoma patients (Livingstone et al, 1994),
induction of anti-GM2 IgM antibodies was demonstrated in a
majority oftreated patients. Vaccination was associated with negli-
gible patient toxicity and borderline prolongation of relapse-free
survival. Since this early study, more efficient carrier systems
and potent immune adjuvants have been developed. Thus,
GM2-KLH/QS-21 vaccine (GM2 conjugated to keyhole limpet
haemocyanin and administered with the immune adjuvant QS-21)
is currently being compared against the Kirkwood regimen in the
USA Intergroup trial of adjuvant therapy in stage IIB and III
malignant melanoma patients. The same ganglioside vaccine is
about to be tested against observation in patients with resected
stage IIA (1.5-4 mm thick) melanomas in Europe. Such vaccines,
being cancer specific and evidently non-toxic to-patients, afford
potential for coupling with IFN-a, but adjuvant combination
studies have as yet not been undertaken.
Finally, it is clear that only a small subset of patients who
received high-dose IFN-a in E1684 derived benefit from it.
Identification of surrogate markers of response will be important
as both future prognostic and therapeutic tools. In E1684, all
patients underwent elective lymph node dissection, which
provided useful staging information, but its role in terms of
survival benefit is controversial. The technique of lymphatic
mapping and sentinel node biopsy was introduced by Morton et al
(1992) as a means of detecting occult nodal metastases, and thus
the offer of selective lymphadenectomy to those patients. Now
combined with intraoperative use of a gamma probe to detect
injected radioactive colloid in addition to blue dye, experienced
operators are able to identify the sentinel node in 99% of cases.
Various investigators have developed reverse transcription poly-
merase chain reaction methods to sensitively and specifically
measure tyrosinase mRNA in sentinel lymph nodes (Wang et al,
1994) and to detect circulating melanoma cells in blood (Smith et
al, 1991; Brossart et al, 1995). Thecurrent USA and EORTC adju-
vant studies are undertaking measurement of such molecular
markers in primary tumour, lymph node tissue and blood of trial
patients. What impact these kind oftechniques will have in terms
of patient selection for therapeutic intervention and subsequent
survival outcome remains to be determined.
FINAL COMMENT
There is accumulating evidence demonstrating that the host's
immunity influences melanomabehaviour. Recent clinical demon-
stration of survival benefit with adjuvant high-dose IFN-a, albeit
in a single randomized clinical trial, was sufficient to justify
licensing of IFN-a for adjuvant use in the UK and to persuade a
growing number of specialists that this is the treatment of choice
for selected patients at high risk of disease recurrence and, ipso
facto, virtual certain death. But before oncologists protest the
imperative forallocating limited resources to fundIFN-a, we must
be sure that the quality ofevidence in favour oftreatmentjustifies
the cost both to the health service and to the patient. If, on
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reviewing the evidence, uncertainty prevails, we have a duty to
address the issues surrounding adjuvant melanoma therapy in a
systematic, controlled manner within the context ofwell-designed
clinical trials. Until such time as E1690 has been analysed,
ongoing adjuvant studies (Aim High and EORTC 18952) should
be supported, and the argument for financing ofIFN-ajustified in
terms offacilitating clinical research offundamental importance.
Experience with adjuvant melanoma trials performed to date
suggests that patient recruitment is difficult. Thus, for future trials,
co-operation with our USA and European colleagues is essential.
By gaining unanimous support from within the oncology disci-
plines, we may better influence govemment, funding agencies,
purchasers and industry for the right drug to be available to the
right people at the right time.
REFERENCES
Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M, Giannotti
B, Queirolo P, Tribbia G, Bemengo MG, Menichetti ET, Palmeri S, Russo A,
Cristofolini M, Erbazzi A, Fowst C, Criscuolo D, Bufalino R, Zilembo N and
Cascinelli N (1994) Multicentre randomized trial ofdacarbazine alone or in
combination with two different schedules ofinterferon alfa-2a in the treatment
of advanced melanoma. J Clin Oncol 12: 806-811
Balch CM, Houghton AN and Peters LJ (1993) Cutaneous melanoma. In Cancer:
Principles and Practice ofOncology, De Vita VT, Hellman S and Rosenberg
SA. (eds), pp. 1612-1661. JB Lippincott: Philadelphia
Balch CM, Reintgen DS, Kirkwood JM, Houghton A, Peter L and Ang KK (1997)
Cutaneous melanoma. In Cancer: Principles and Practice ofOncology, DeVita
VT, Hellman S and Rosenberg SA. (eds) pp. 1947-1994. Lippincott-Raven
Publishers: Philadelphia
Bleehan NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJS,
Brampton M and Stevens MFG (1995) Cancer Research Campaign phase II
trial oftemozolamide in metastatic melanoma. J Clin Oncol 13: 910-913
Brossart P, Schmier J, Kruger S, Willhauck M, Scheibenbogen C, Mohler T and
Keilholz U (1995) A polymerase chain reaction-based semiquantitative
assessment ofmalignant melanoma cells in peripheral blood. Cancer Res 55:
4065-4068
Cascinelli N (1995) Evaluation ofefficacy ofadjuvant rIFNaz 2a in melanoma
patients with regional node metastases (abstract). Proc Am Soc Clin Oncol 14:
410
Cascinelli N, Bufalino R, Morabito A and Mackie R (1994) Results ofadjuvant
interferon study in WHO melanoma programme (letter). Lancet343: 913-914
Coates A, Rallings M, Hersey P and Swanson C (1986) Phase II study of
recombinant alpha 2-interferon in advanced malignant melanoma. JInterferon
Res 6: 1-4
Cole BF, Gelber RD. Kirkwood JM, Goldhirsch A, Barylak E and Borden E (1996)
Quality-of-life-adjusted survival analysis ofinterferon alfa-2b adjuvant
treatment ofhigh-risk resected cutaneous melanoma: an Eastem Cooperative
Oncology Group study. J Clin Oncol 14: 2666-2673
Creagan ET, Ahmann DL, Green SJ, Long HJ, Rubin J, Schutt AJ and
Dziewanowski ZE (1984) Phase II study oflow-dose recombinant leukocyte A
interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 54:
2844-2849
Creagan ET, Loprinzi CL, Ahmann DL and Schaid DJ (1988) A phase I-II trial of
the combination ofrecombinant leukocyte A interferon and recombinant
human interferon-gamma in patients with metastatic malignant melanoma.
Cancer 62: 2472-2474
Creagan ET, Dalton RJ, Ahmann DL, Jung S-H, Morton RF, Langdon RM, Kugler J
and Rodrigue LJ (1995) Randomized, surgical adjuvant trial ofrecombinant
interferon-alfa-2a in selected patients with malignant melanoma. J Clin Oncol
13: 2776-2783
Dorval T, Palangie T, Jouve M, Garcia-Giralt E, Israel L, Falcoff E, Schwab D and
Pouillart P (1986) Clinical phase II trial ofrecombinant DNA interferon
(interferon alfa 2b) in patients with metastatic malignant melanoma. Cancer
58: 215-218
Elsasser-Beile U and Drews H (1987) Interferon in the treatment ofmalignant
melanoma: results ofclinical studies. Fortschr Med 105: 401-403
Falkson CI, Falkson G and Falkson H (1991) Improved results with the addition of
interferon alfa-2b to dacarbazine in the treatment ofpatients with metastatic
malignant melanoma. J Clin Oncol 9: 1403-1408
Falkson CI, Ibrahim J, Kirkwood J and Blum R (1996) A randomized phase III trial
ofdacarbazine (DTIC) versus DTIC + interferon alfa2b (rIFN) versus DTIC +
tamoxifen (TMX) versus DTIC + rIFN + TMX in metastatic malignant
melanoma: and ECOG trial (abstract). ProcAm Soc Clin Oncol 15: 435
Fisher RI, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG and Fisher
SG (1981) Adjuvant immunotherapy or chemotherapy for malignant
melanoma: preliminary report ofthe National Cancer Institute randomized
clinical trial. Surg Clin North Am 61: 1267-1277
Grob JJ, Dreno B, Delaunay M, Chastang C, Guillot B, Cupissol B, Souteyrand P,
Sassolas B, Cesarini JP, Thivolet J, Denoeux JP, Ortanne JP, Thomas L, Beylot
C, Truchetet F, Lovette G, Chemaly C, Meynadier J, Amblard P, Thyss P, Avril
MF, Prigent F and Bonerandi JJ (1996) Results ofthe French multicentre trial
on adjuvant therapy with interferon alfa-2a in resected primary melanoma
(> 1.5 mm) (abstract). ProcAm Soc Clin Oncol 15: 437
Hersey P, Hasic E, Macdonald M, Edwards A, Spurling A, Coates AS, Milton GW
and McCarthy WH (1985) Effects ofrecombinant leukocyte interferon (rIFN-
alpha A) on tumour growth and immune responses in patients with metastatic
melanoma. BrJ Cancer 51: 815-826
Hillner BE, Kirkwood JM, Atkins MB, Johnson ER and Smith TJ (1997) Economic
analysis ofadjuvant interferon-alfa 2b in high risk melanoma based on
projections from Eastem Cooperative Oncology Group 1684. J Clin Oncol 15:
2351-2358
Kaiser LR, Burk MW and Morton DI (1981) Adjuvant therapy for malignant
melanoma. Surg Clin NorthAm 61: 1249-1257
Kerin MJ, Gillen P, Monson JR, Wilkie J, Keane FB and Tanner WA (1995) Results
ofa prospective randomized trial using DTIC and interferon as adjuvant
therapy for stage I malignant melanoma. EurJSurg Oncol 21: 548-550
Kirkwood JM, EmstoffMS, Davis CA, Reiss M, Ferraresi R and Rudnick SA (1985)
Comparison of intramuscular and intravenous recombinant alpha-2 interferon
in melanoma and other cancers. Ann Intern Med 103: 32-36
Kirkwood JM, Strawderman MH, EmstoffMS, Smith TJ, Borden EC and Blum RH
(1996) Interferon alfa-2b adjuvant therapy ofhigh-risk resected cutaneous
melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin
Oncol 14: 7-17
Legha SS (1997) The role ofinterferon alfa in the treatment ofmetastatic melanoma.
Sem Oncol 24: 24-31
Legha SS, Papadopoulos NE, Plager C, Ring S, Chawla SP, Evans LM and
Benjamin RS (1987) Clinical evaluation ofrecombinant interferon alfa-2a
(Roferon-A) in metastatic melanoma using two different schedules. J Clin
Oncol5: 1240-1246
Livingstone PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C,
Calves MJ, Helling F, Ritter G, Oettgen HF and Old LJ (1994) Improved
survival in stage III melanoma patients with GM2 antibodies: a randomized
trial ofadjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:
1036-1044
McClay EF and McClay M-ET (1996) Systemic chemotherapy for the treatment of
metastatic melanoma. Sem Oncol 23: 744-753
Meisenberg BR, Ross M, Vredenburgh JJ, Jones R, Shpall EJ, Seigler HF, Coniglio
DM, Wu K and Peters WP (1993) Randomized trial ofhigh-dose chemotherapy
with autologous bone marrow support as adjuvant therapy for high-risk, multi-
node positive malignant melanoma. JNatl Cancer Inst 85: 1080-1085
Meyskens FL Jr, Kopecky K, Samson M, Hersh E, Macdonald J, Jaffe H, Crowley J
and Coltman C (1990) Recombinant human interferon-y: adverse effects in
high-risk stage I and II cutaneous malignant melanoma (letter). JNatl Cancer
Inst82: 1071
Meyskens FL, Liu P, Tuthill RJ, Sondak VK, Fletcher WS and Jewell WR (1994)
Randomized trial ofvitamin A versus observation as adjuvant therapy in high-
risk primary malignant melanoma: a Southwest Oncology Group study. J Clin
Oncol 12: 2060-2065
Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun
IG, Doroshow JH, Flaherty LE and Sondak VK (1995) Randomized trial of
adjuvant human interferon gamma versus observation in high-risk cutaneous
melanoma: a Southwest Oncology Group study. JNatl Cancer Inst 87:
1710-1713
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ and
Cochran AJ (1992) Technical details ofintraoperative lympathic mapping for
early-stage melanoma. Arch Surg 127: 392-399
Office ofPopulation Censuses and Surveys (1994) Cancer statistics: registrations of
cancer diagnosed in 1988, Englandand Wales. HMSO: London
Parkinson DR (1991) Levamisole as adjuvant therapy for melanoma: quo vadis?
J Clin Oncol 9: 2052
Robinson WA, Mughal TI, Thomas MR, Johnson M and Spiegel RJ (1986)
Treatment ofmetastatic malignant melanoma with recombinant interferon
alpha 2. Immunobiology 172: 275-282
British Journal ofCancer (1998) 77(8), 1287-1293 C CancerResearch Campaign 1998Adjuvant therapy formelanoma 1293
Sertoli MR, Bemengo MG, Ardizzoni A, Brunetti I, Falcone A, Vidili MG,
Cusimano MP, Appino A, Doveil G and Fortini C (1989) Phase H trial of
recombinant alpha-2b interferon in the treatment ofmetastatic skin melanoma.
Oncology 46: 96-98
Smith B, Selby P, Southgate J, Pitman K, Bradley C and BlairGE (1991) Detection
ofmelanoma cells in peripheral blood by means ofreverse transcriptase and
polymerase chain reaction. Lancet 388: 1227-1229
Spitler LE (1991) A randomized trial oflevamisole versus placebo as adjuvant
therapy in malignant melanoma. J Clin Oncol 9: 736-740
Steiner A, WolfC and Pehamberger H (1987) Comparison ofthe effects ofthree
different treatment regimens ofrecombinant interferons (rIFN alpha, rIFN
gamma and rIFN alpha + cimetidine) in disseminated malignant melanoma.
J CancerRes Clin Oncol 113: 459-465
Tan JK and Ho VC (1993) Pooled analysis ofthe efficacy ofbacille Calmette-Guerin
(BCG) immunotherapy in malignant melanoma. JDermatol Surg Oncol 19:
985-990
Thomson DB, Adena M, McCleod GR, Hersey P, Gill PG, Coates AS, Olver In,
Kefford RF and Lowenthal RM (1993) Interferon alpha 2a does not improve
response or survival when combined with dacarbazine in metastatic malignant
melanoma: results ofa multi-institutional Australian randomized trial.
Melanoma Res 3: 133-138
Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R,
Cascinelli N, Cocconi G, Durand J, De Marsillac J, Ikonopisov RL, Kiss B,
Lejeune F, Mackie R, Madej G, Mulder H, Mechl Z, Milton GW, Morabito A,
Peter H, Priario J, Paul E, Rumke P, Sertoli R and Tomin R (1982) A
randomised trial ofadjuvant chemotherapy and immunotherapy in cutaneous
melanoma. New EnglJMed307: 913-916
Wang X, Heller R, Vanvoorhis N, Cruse CW, Glass F, Fenske N, Berman C, Leo-
Messina J, Rappaport D and Wells K (1994) Detection ofsubmicroscopic
metastases with polymerase chain reaction in patients with malignant
melanoma. Ann Surg 220: 768-774
Williams MV, de Takats PG and Parmer M (1997) Survival benefit in melanoma.
J Clin Oncol 15: 2172
© Cancer Research Campaign 1998 British Journal ofCancer(1998) 77(8), 1287-1293